Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism:A randomized, crossover trial

Clinical Nephrology

Volumn 71, Issue 6, 2009, Pages 660-668

  Ito, H ^a   Ogata, H ^a,d   Yamamoto, M ^a   Takahashi, K ^b   Shishido, K ^b   Takahashi, J ^c   Taguchi, S ^a   Kinugasa, E ^a  

^a SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^b Sekishin kai Kawasaki Clinic   (Japan)

^c Sohwa kai Eda Clinic   (Japan)

^d NONE   (Japan)

Author keywords

Calcitriol; CKD MBD; Falecalcitriol; Secondary hyperparathyroidism (SHPT)

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLLAGEN TYPE 1; FALECALCITRIOL; INTACT PARATHYROID HORMONE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; UNCLASSIFIED DRUG; WHOLE PARATHYROID HORMONE; 26,26,26,27,27,27-HEXAFLUORO-1,25-DIHYDROXYVITAMIN D3; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; DRUG DERIVATIVE; PEPTIDE; PHOSPHORUS;

ADULT; AGED; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; MINERAL METABOLISM; MORNING DOSAGE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; BLOOD; BONE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; COLLAGEN TYPE I; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDES; PHOSPHORUS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 67651012549     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71660     Document Type: Article

References (34)

1. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998; 32: 238-246.
2. Akizawa T, Kamimura M, Mizobuchi M, Shiizaki K, Sumikado S, Sakaguchi T, Negi S, Ogata H, Kinugasa E. Management of secondary hyperparathyroidism of dialysis patients. Nephrology (Carlton). 2003a; 8 (Suppl): 53-57.
3. Akizawa T, Shiizaki K, Hatamura I, Kamimura M, Mizobuchi M, Narukawa N, Sumikado S, Sakaguchi T, Negi S, Ogata H, Kinugasa E. New strategies for the treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2003b; 41: 100-103.
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-617.
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
6. Brown AJ. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J Steroid Biochem Mol Biol. 2007; 103: 578-583.
7. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002; 17 (Suppl) 10: 10-19.
8. Ferreira A, Drueke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci. 2000; 320: 85-89.
9. Fischer ER, Harris DC. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 1993; 40: 216-220.
10. Imanishi Y, Inaba M, Seki H, Koyama H, Nishizawa Y, Morii H, Otani S. Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells. J Steroid Biochem Mol Biol. 1999; 70: 243-248.
11. Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R. Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients (in Japanese). Clin Calcium. 2006; 16: 847-851.
12. Kiriyama T, Okamoto S, Ejima E, Kurihara N, Hakeda Y, Ito N, Izumi M, Kumegawa M, Nagataki S. Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology. 1991; 128: 81-86.
13. Kiriyama T, Okamoto S, Suzuki H, Nagata A, Izumi M, Morii H, Nagataki S. Biological activity of 26,26,26, 27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in the chick. Acta Endocrinol (Copenh). 1989; 121: 520-524.
14. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial. 2008; 12: 42-48.
15. Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab. 1994; 20: 97-102.
16. McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease. Kidney Int. 1999; 55: 500-511.
17. Miyahara T, Simoura T, Osahune N, Uchida Y, Sakuma T, Nemoto N, Kozakai A, Takamura T, Yamazaki R, Higuchi S, Chiba H, Iba K, Sawada N. A highly potent 26,27-Hexafluoro-1a,25-dihydroxyvitamin D3 on calcification in SV40-transformed human fetal osteoblastic cells. Calcif Tissue Int. 2002; 70: 488-495.
18. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003; 23: 369-379.
19. Morii H. Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism (in Japanese). Clin Calcium. 2005; 15: 29-33.
20. Ogata H, Koiwa F, Ito H, Kinugasa E. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Ther Apher Dial. 2006; 10: 355-363.
21. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol. 2007; 11: 261-268.
22. Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial. 2005; 9: 11-15.
23. Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2007; 11: 202-209.
24. Ohtsuka N, Urayama K. Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3 (in Japanese). Nippon Yakurigaku Zasshi. 2002; 120: 427-436.
25. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4: 643-646.
26. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994; 45: 1710-1721.
27. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999; 56: 383-392.
28. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19: 179-184.
29. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984; 74: 2136-2143.
30. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
31. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125.
32. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient. Clin Nephrol. 2008; 69: 393.
33. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55: 2141-2156.
34. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.